TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06187441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide capsule
Description: Patients who have been treated with 12 cycles of Daratumumab-Lenalidomide-Dexamethasone (Dara-Rd) will be randomized between Arm A (continuous therapy) and Arm B (treatment free interval)
Study: NCT04871438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Description: Group A will use FreeStyle Libre for two weeks of FGM-based titration of medications at two time-points: 1) At recruitment and 2) At 6 weeks. Outside of these time points, they will use SMBG (standard care) for monitoring of blood glucose.
Study: NCT05831449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection of CPL-01
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin, 0.5% Injectable Solution
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local anesthetic injection (either IP, positive control \[Naropin\], or negative control \[saline placebo\])
Study: NCT04543682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125 ng/kg/min Iloprost
Description: Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 ng/kg/min Iloprost
Description: Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours

Intervention type: PROCEDURE
Group type: OTHER
Intervention: open reduction and internal fixation with an angular stable plate (PHILOS)
Description: open reduction and internal fixation with an angular stable plate (PHILOS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open reduction and internal fixation with an angular stable plate (PHILOS)
Description: open reduction and internal fixation with an angular stable plate (PHILOS)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open reduction and internal fixation with an angular stable plate (PHILOS)
Description: open reduction and internal fixation with an angular stable plate (PHILOS)
Study: NCT05810948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod IV
Description: Intravenous (IV) infusion of efgartigimod

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion of placebo
Study: NCT04704401

Intervention type: OTHER
Intervention: Questionnaire
Description: Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
Study: NCT05294731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered
Study: NCT05265351

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transdiaphragmatic pressure measurement
Description: Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EMG
Description: Surface electromyography of the diaphragm for phrenic nerve conduction study
Study: NCT06258278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted lower trapezius tendon transfer surgery
Description: The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
Study: NCT06075056

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention is planned as part of this study, this is a feasibility/pilot study
Study: NCT04767880

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains \<1 kcal and 0 g protein
Study: NCT05393154

Intervention type: DEVICE
Intervention: Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner
Description: Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
Study: NCT04590612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Description: 25mg-100mg tablets to be taken orally three times a day on an empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 20 mg tablet to be taken orally once and at the same time of the day, daily.
Study: NCT06435715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 Repetitions of Deep Breathing Exercise
Description: Respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days.
Study: NCT05770648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Annuloplasty
Description: Under the guidance of ultrasound, the transcatheter tricuspid ring forming system accurately reaches the designated position of the tricuspid valve region through the jugular vein and superior vena cava approach. The expanded tricuspid ring tissue is clammed together with the clamping parts and anchor parts, and the circumference of the tricuspid ring is reduced, thus reducing the area of the opening of the tricuspid valve that cannot be closed originally, and achieving the purpose of minimally invasive treatment of tricuspid regurgitation.

Intervention type: OTHER
Group type: OTHER
Intervention: The guidelines guide medication
Description: The guidelines guide medication
Study: NCT04855227

Intervention type: PROCEDURE
Intervention: robotic-assisted ventral hernia repair
Description: Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.
Study: NCT03668041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
Study: NCT05746806

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy
Description: Ultrahypofractioned radiotherapy for patients with isolated local recurrence after radical prostatectomy in 5 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: In combination to the radiotherapy a short term androgen deprivation drug for 6 months will be applied.~The drug concept used is:~- LHRH(Luteinizing hormone releasing hormone)-agonist with 3-month subcutaneous depot injection (e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.) in combination with nonsteroidal antiandrogen (e.g. Bicalutamide 50mg/day) as flare protection at least 5 days before and max. 15 days after first LHRH-injection
Study: NCT04396873

Intervention type: DRUG
Group type: OTHER
Intervention: 11C-MC1
Description: Injected IV followed by PET scanning

Intervention type: DRUG
Group type: OTHER
Intervention: 11C-PS13
Description: Injected IV followed by PET scanning

Intervention type: DRUG
Group type: OTHER
Intervention: 18f-florbetaben
Description: Injected IV followed by PET scanning
Study: NCT06237049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 (Omi XBB.1.5)/RIV
Description: Combination of BNT162b2 (Omi XBB.1.5) and RIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 (Omi XBB.1.5)
Description: Licensed COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 (Omi XBB.1.5)
Description: Licensed COVID-19 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIV
Description: Licensed recombinant influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RIV
Description: Licensed recombinant influenza vaccine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline placebo
Description: Normal saline (solution for injection)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline placebo
Description: Normal saline (solution for injection)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline placebo
Description: Normal saline (solution for injection)
Study: NCT05521984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of care
Study: NCT05324501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX110
Description: Soluble panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX110
Description: Soluble panobinostat

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable pump and catheter system
Description: To allow Convection-Enhanced Delivery (CED)
Study: NCT05521984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of care
Study: NCT05686122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainPac
Description: Patient-focused behavioral pain intervention delivered via mobile application.
Study: NCT06087289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND567
Description: KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND567
Description: KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
Study: NCT00629213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Study: NCT06435715

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 Repetitions of Deep Breathing Exercise
Description: Respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.
Study: NCT05324501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable pump and catheter system
Description: To allow Convection-Enhanced Delivery (CED)
Study: NCT05246280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT05127265

Intervention type: OTHER
Intervention: Video Monitoring
Description: continuous video monitoring

Intervention type: OTHER
Intervention: Accelerometer Monitoring
Description: continuous accelerometer monitoring of patient movements

Intervention type: OTHER
Intervention: Noise Level Monitoring
Description: continuous environmental noise monitoring

Intervention type: OTHER
Intervention: Light Level Monitoring
Description: continuous environmental light monitoring

Intervention type: OTHER
Intervention: Air Quality Monitoring
Description: continuous environmental air quality monitoring

Intervention type: OTHER
Intervention: EKG Monitoring
Description: continuous EKG monitoring

Intervention type: OTHER
Intervention: Vitals Monitoring
Description: continuous vitals monitoring (heart rate, oxygen saturation)

Intervention type: OTHER
Intervention: Biosample Collection
Description: blood and urine samples collected once on Day 1 and once on Day 2

Intervention type: OTHER
Intervention: Delirium Motor Subtyping Scale 4 (DMSS-4)
Description: done daily on delirious patients to subtype delirium
Study: NCT05699018

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: eLIFT
Description: Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
Study: NCT05565924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.
Description: Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Group- E; Control group
Description: Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study.
Study: NCT05977543

Intervention type: OTHER
Group type: OTHER
Intervention: Functional crackers enriched with grape seed flour
Description: The crackers was enriched with 10% grape seed flour

Intervention type: OTHER
Group type: OTHER
Intervention: Functional crackers with 40% barley flour and enriched with β-glucans
Description: The crackers consisted of 60% wheat flour, 40% barley flour and was enriched with β-glucans.
Study: NCT06087289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
Study: NCT06649435

Intervention type: PROCEDURE
Intervention: PPG measurement
Description: PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.~Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart.

Intervention type: PROCEDURE
Intervention: PPG measurement
Description: PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.~Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart.